Bio4Dreams enters OaCP as a shareholder and investor and launches a tailored incubation program to support the company’s growth strategy in the European market and its expansion into the U.S. and Arab markets.

OaCP: solutions for more efficient diagnostics by optimizing time and costs

OaCP is an innovative company based in Cork, Ireland, originating from a research project at the University of Bologna. The company develops reagents for oncology diagnostics that make DNA testing faster and more cost-effective.

Its products are already commercialized in Italy and across Europe and are used by leading hospitals, laboratories, and research centers.

The next objective is to accelerate growth in these markets and expand into new ones, including the Arab region and the United States. In this context, and supported by new financial resources, OaCP aims to undertake the FDA regulatory approval process for its reagents.

Equity entry, investment, and incubation: Bio4Dreams’ support for OaCP

Bio4Dreams has entered OaCP’s share capital as a shareholder and completed a co-investment through a SAFE (Simple Agreement for Future Equity), an instrument that allows capital to be invested today and converted into equity at a later stage.

In parallel, an incubation program has been launched to support OaCP strategically in strengthening its current markets and scaling its international expansion.

The transaction builds on a collaboration that has been active for several years. As early as 2022, OaCP joined the Bio4Dreams ecosystem through its membership, which has been renewed in subsequent years, confirming the continuity and strength of the relationship.

This step further enhances Bio4Dreams’ local positioning in the Emilia-Romagna Region, where OaCP has strong territorial ties, as well as its international footprint, reinforcing its ability to activate connections between European ecosystems and strategic global markets. For OaCP, the transaction provides access to resources, expertise, and networks essential to accelerate growth, expand commercial presence, and structure entry into new geographies.

“Strengthening our partnership with Bio4Dreams represents a key accelerator in OaCP’s expansion journey. Bio4Dreams’ entry into our share capital and the strategic support provided by the incubator give us the resources and expertise needed to confidently address the FDA regulatory pathway and scale our presence in both the U.S. and Arab markets. We are ready to transform the efficiency of oncology diagnostics on a global scale, bringing our innovative solutions to an increasing number of research centers and hospitals.”

Enrico Di Oto, CEO, OaCP

“We have been working side by side with OaCP for years and are well aware of its value: a team that combines scientific rigor with entrepreneurial vision. Today, we have chosen to take a further step by integrating expertise, methodology, and network. Our goal is to support shared growth in Europe and facilitate access to new international markets.”

Demetra Pelos, Strategic Projects Director & Head of Business Nursery, Bio4Dreams

📗 Learn more about OaCP and the other companies in our portfolio.